(Q53238557)

12 May 2018

title

EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. (English)

1 reference

12 May 2018

1 reference

1 reference

Shahreen Billah

1

1 reference

12 May 2018

John Stewart

2

1 reference

12 May 2018

Gregg Staerkel

3

1 reference

12 May 2018

Su Chen

4

1 reference

12 May 2018

Yun Gong

5

1 reference

12 May 2018

Ming Guo

6

1 reference

12 May 2018

publication date

11 March 2011

1 reference

12 May 2018

number of pages

7

1 reference

inferred from page(s)

published in

Cancer Cytopathology

1 reference

12 May 2018

volume

119

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

111-117

1 reference

12 May 2018

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Chemotherapy for advanced stage non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

The emerging role of biomarkers in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

7 January 2021

inferred from DOI database lookup

Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

7 January 2021

inferred from DOI database lookup

Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20151

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/CNCY.20151

1 reference

12 May 2018

PubMed ID

21400670

1 reference

12 May 2018